3 Biotechnology stocks under 10 dollars to buy now
Here are three inexpensive biotech stocks with a bright future ahead of them.
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.
2022-11-26 11:30

Biotechnology stocks are a hot commodity but can be hard to find. This is especially true regarding small-cap biotechs traded over the counter (OTC). But there are some great options out there for investors who want exposure to this exciting market segment but don't want to spend a lot of time looking through massive portfolios of companies.
 3 Biotechnology stocks under 10 dollars to buy now
Here are three inexpensive biotech stocks with a bright future ahead of them:

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
BioCryst Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for rare diseases. The company's lead product candidate, BCX4430, is an orally-administered antibody-drug conjugate (ADC) that targets the HER2 oncogene and has been designated a monotherapy. The ADC platform has the potential to address unmet medical needs in cancer patients by combining targeted therapy with an antibody against tumor cells or other substances that are readily available in nature.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is down about one percent in a 1-year timeframe. It has managed to maintain stability despite this year's market selloff. The Q3 earnings report for BioCryst Pharmaceuticals, Inc is also a pointer to getting into this stock. They have smashed earnings twice over the last 4 quarters. Revenue for Q3 came at 78 million USD, which is almost 100 percent compared to YOY.

Trust me; this stock has outperformed the s&p this year already. It has more to offer on the upside.

Cerus Corporation (NASDAQ: CERS)
Cerus is a clinical-stage biopharmaceutical company that develops, manufactures, and commercializes medical products to prevent blood transfusion-transmitted infections. The company's lead product candidate, CER-3100, is an investigational new drug (IND)-enabling product based on proprietary technology to prevent infection following transfusion of contaminated blood or organs. The company is also developing two additional IND candidates: CER-3100/CER-3007 (a combination therapy) and CER-3008 (a monotherapy). This stock is currently trading at 3.83 USD.

I see this stock hitting 6 USD if they get successful with their clinical trials.

Eyenovia Inc. (NASDAQ:EYEN)
Eyenovia Inc. (NASDAQ: EYEN) is another biotech company that develops and commercializes a broad portfolio of products to prevent and treat eye infections. The company's lead product is ZOSYN, which treats bacterial conjunctivitis – an inflammation or irritation of the eyelids, tear ducts, and surrounding structures caused by bacteria or viruses. It also has two other drugs in development – UBIZYN (for bacterial trachoma) and EYENOVIRON-F (for fungal keratitis).

Eyenovia Inc. is expected to grow its revenue by about 71 per annum over 3 years, significantly more significant than the pharmaceutical industry, which is forecasted to grow at 4 percent per year. The current market capitalization sits at $20 million, but it could double by year-end if you choose the right stocks now - so think about this option before buying anything else!

As you can see, some great biotech stocks we've come across over the past few weeks are under $10. This list of cheap stocks will help you find one that suits your needs.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

Published On
2022-11-26 11:30

About the Author
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.

You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

What on Earth Happened to SVB Financial Group (SIVB)?
What is in Store for Silicon Valley Bank?
By Mike Sakuraba | 1 week ago

2 Tech Stocks to Consider for the Long Term
Even with all of the bearishness in the markets, as investors, we should be looking for quality stocks.
By Mike Sakuraba | 1 week ago

Why Tesla's Recent Event Failed to Deliver
Tesla's recent event failed to meet investors' expectations due to the lack of a Next Generation EV announcement.
By Staff | 2 weeks ago

Qualcomm's partnership with Iridium takes connectivity to new heights
Qualcomm's partnership with Iridium brings satellite-based messaging technology to phones, laptops and other devices, providing new opportunities for connectivity in any location.
By Staff | 2 months ago

Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year
Hologic has managed to achieve impressive financial results in Fiscal Q1 2023.
By Staff | 2 months ago

Why Small and Mid-Cap Stocks Deserve Your Attention
Why valuations make small and mid-cap stocks an attractive option in a potential recession.
By Staff | 2 months ago

Get Ready for a Bumpy Year
Despite strong job creation numbers, deeper issues lurk beneath the surface as the Federal Reserve's rate hikes and high inflation threaten to derail the economy.
By Staff | 2 months ago